Biology of CCR5 and its role in HIV infection and treatment

被引:204
作者
Lederman, Michael M.
Penn-Nicholson, Adam
Cho, Michael
Mosier, Donald
机构
[1] Case Western Reserve Univ, Sch Med, Univ Hosp Cleveland, Ctr AIDS Res, Cleveland, OH USA
[2] Scripps Res Inst, La Jolla, CA 92037 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2006年 / 296卷 / 07期
关键词
D O I
10.1001/jama.296.7.815
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chemokine receptors are found on cell surfaces and promote cellular migration by chemotaxis. The CC chemokine receptor 5 (CCR5) is used by the human immunodeficiency virus (HIV) to infect cells. Strategies that target human CCR5 are therefore being developed to prevent and treat HIV infection. Antiviral strategies that target a host element necessary for viral replication may be predicted to interfere with the function of that element and may therefore adversely affect the host. We conducted a review of the literature between November 2005 and April 2006 with a focus on articles addressing the genetics and function of CCR5, the effects of CCR5 deletion in human and murine systems, and treatment strategies for HIV infection that target this coreceptor. English-language articles in the human and murine literature published between March 1996 and April 2006 were identified through a search of MEDLINE using CCR5 as the search term. Relevant articles as judged by their titles and abstracts were reviewed in detail. In addition, based on our knowledge of the field and with permission, unpublished work was also reviewed. In this article, we explore the effects that targeting CCR5 may have on host defenses in individuals with immunity already compromised by HIV infection.
引用
收藏
页码:815 / 826
页数:12
相关论文
共 112 条
[71]   A controlled trial of natalizumab for relapsing multiple sclerosis. [J].
Miller, DH ;
Khan, OA ;
Sheremata, WA ;
Blumhardt, LD ;
Rice, GPA ;
Libonati, MA ;
Willmer-Hulme, AJ ;
Dalton, CM ;
Miszkiel, KA ;
O'Connor, PW .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01) :15-23
[72]   T cell costimulation by chemokine receptors [J].
Molon, B ;
Gri, G ;
Bettella, M ;
Gómez-Moutón, C ;
Lanzavecchia, A ;
Martínez-A, C ;
Mañes, S ;
Viola, A .
NATURE IMMUNOLOGY, 2005, 6 (05) :465-471
[73]   Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection [J].
Moyle, GJ ;
Wildfire, A ;
Mandalia, S ;
Mayer, H ;
Goodrich, J ;
Whitcomb, J ;
Gazzard, BG .
JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (06) :866-872
[74]   The chemokine receptor, CCR5 [J].
Mueller, A ;
Strange, PG .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (01) :35-38
[75]  
MURPHY PM, 2003, FUNDAMENTAL IMMUNOLO, P801
[76]   A CONSERVED NEUTRALIZING EPITOPE ON GP41 OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
MUSTER, T ;
STEINDL, F ;
PURTSCHER, M ;
TRKOLA, A ;
KLIMA, A ;
HIMMLER, G ;
RUKER, F ;
KATINGER, H .
JOURNAL OF VIROLOGY, 1993, 67 (11) :6642-6647
[77]   The role of CC chemokine receptor 5 in antiviral immunity [J].
Nansen, A ;
Christensen, JP ;
Andreasen, SO ;
Bartholdy, C ;
Christensen, JE ;
Thomsen, AR .
BLOOD, 2002, 99 (04) :1237-1245
[78]   Tumour necrosis factor inhibitors [J].
Nash, PT ;
Florin, THJ .
MEDICAL JOURNAL OF AUSTRALIA, 2005, 183 (04) :205-208
[79]  
Nieto M, 1998, J IMMUNOL, V161, P3330
[80]   Chemokine receptor CCR5: insights into structure, function, and regulation [J].
Oppermann, M .
CELLULAR SIGNALLING, 2004, 16 (11) :1201-1210